Advertisement

International Journal of Colorectal Disease

, Volume 24, Issue 2, pp 145–150 | Cite as

Survivin -31G/C promoter polymorphism and sporadic colorectal cancer

  • Maria Gazouli
  • Nikolaos Tzanakis
  • George Rallis
  • George Theodoropoulos
  • Ioannis Papaconstantinou
  • Alkiviadis Kostakis
  • Nicholas P. Anagnou
  • Nikolaos NikiteasEmail author
Original Article

Abstract

Introduction

Survivin is an apoptotic inhibitor, plays an important role in cell cycle regulation, and may be involved in the development and progression of cancer. A common polymorphism at the survivin gene promoter (-31 G/C) has been shown to influence survivin expression and the risk for cancer.

Aim

The aim of the present study was to investigate whether this polymorphism could be involved in the sporadic colorectal cancer (CRC) development, prognosis, and survival.

Materials and methods

The -31G/C polymorphism of survivin promoter was analyzed by polymerase chain reaction (PCR) restriction fragment length polymorphism method in biopsies from 312 patients with sporadic CRC and 362 healthy individuals. Survivin messenger RNA (mRNA) expression in CRC tissues was detected by quantitative reverse transcriptase PCR.

Results and discussion

The genotype frequencies for -31GG, -31GC, and -31CC were 21.79%, 41.99%, and 36.22% in CRC patients and 33.98%, 45.03%, and 20.99% in healthy subjects, respectively. The frequencies of the survivin -31C allele and CC genotype were significantly higher in CRC patients than in healthy subjects (p < 0.0001). Homozygotes for the -31CC survivin genotype, expressed 1.6-fold higher mRNA levels of survivin compared to cases with the -31GG and -31GC genotypes.

Conclusion

The -31CC genotype of survivin promoter is associated with CRC and may be a risk factor for CRC.

Keywords

Survivin -31G/C polymorphism Colorectal cancer 

References

  1. 1.
    Thompson CB (1995) Apoptosis is the pathogenesis and treatment of disease. Science 267:1456–62PubMedCrossRefGoogle Scholar
  2. 2.
    Raff M (1998) Cell suicide for beginners. Nature 396:119–22PubMedCrossRefGoogle Scholar
  3. 3.
    Ambrosini G, Adida C, Alteri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–21PubMedCrossRefGoogle Scholar
  4. 4.
    Deveraux QL, Reed JC (1999) IAP family proteins—suppressors of apoptosis. Genes Dev 13:239–252PubMedCrossRefGoogle Scholar
  5. 5.
    Li F, Ambrosini G, Chu EY et al (1998) Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396:580–584PubMedCrossRefGoogle Scholar
  6. 6.
    Altieri DC (2001) The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol Med 7:542–547PubMedCrossRefGoogle Scholar
  7. 7.
    Liston P, Fong WG, Korneluk RG (2003) The inhibitors of apoptosis: there is more to life than Bcl2. Oncogene 22:8568–8580PubMedCrossRefGoogle Scholar
  8. 8.
    Yamamoto T, Tanigawa N (2001) The role of surviving as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 34:207–212PubMedCrossRefGoogle Scholar
  9. 9.
    Tamm I, Wang Y, Sausville E et al (1998) IAP-family protein surviving inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 58:5315–5320PubMedGoogle Scholar
  10. 10.
    Asanuma K, Moriai R, Yajima T et al (2000) Survivin as a radioresistance factor in pancreatic cancer. Jpn J Cancer Res 91:1204–1209PubMedGoogle Scholar
  11. 11.
    Velculescu VE, Madden SL, Zhang L et al (1999) Analysis of human transcriptomes. Nat Genet 4:387–388CrossRefGoogle Scholar
  12. 12.
    Altieri DC, Marchisio PC, Marchisio C (1999) Survivin apoptosis: an interloper between cell death and cell proliferation in cancer. Lab Invest 79:1327–1333PubMedGoogle Scholar
  13. 13.
    Xu Y, Fang F, Ludewig G et al (2004) A mutation found in the promoter region of the human survivin gene is correlated to overexpression of survivin in cancer cells. DNA Cell Biol 23:527–537PubMedGoogle Scholar
  14. 14.
    Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal carcinoma. Cell 87:159–170PubMedCrossRefGoogle Scholar
  15. 15.
    Sarela A, Macadam R, Farmery S, Markham A, Guillou P (2000) Expression of the antiapoptosis gene, Survivin, predicts death from recurrent colorectal carcinoma. Gut 465:645–650CrossRefGoogle Scholar
  16. 16.
    Kawasaki H, Altieri DC, Lu CD et al (1998) Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071–5074PubMedGoogle Scholar
  17. 17.
    Borbely AA, Murvai M, Szarka K et al (2007) Survivin promoter polymorphism and cervical carcinogenesis. J Clin Pathol 60:303–306PubMedCrossRefGoogle Scholar
  18. 18.
    Jang JS, Kim KM, Kang KH et al (2008) Polymorphisms in the survivin gene and the risk of lung cancer. Lung Cancer 60:31–39PubMedCrossRefGoogle Scholar
  19. 19.
    Cheng ZJ, Hu LH, Huang SJ (2008) Correlation of -31G/C polymorphisms of surviving promoter to tumorigenesis of gastric carcinoma. Ai Zheng 27:258–263PubMedGoogle Scholar
  20. 20.
    Morson BC, Sobin LH (1976) Histologic typing of intestinal tumours: WHO technical report. WHO, GenevaGoogle Scholar
  21. 21.
    Sobin LH, Wittekind C (1997) UICC TNM classification of malignant tumours. Fifth Edition. Wiley-Liss, New YorkGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Maria Gazouli
    • 1
  • Nikolaos Tzanakis
    • 2
  • George Rallis
    • 3
  • George Theodoropoulos
    • 4
  • Ioannis Papaconstantinou
    • 5
  • Alkiviadis Kostakis
    • 2
  • Nicholas P. Anagnou
    • 1
    • 6
  • Nikolaos Nikiteas
    • 2
    Email author
  1. 1.Department of BiologySchool of Medicine,University of Athens, GreeceAthensGreece
  2. 2.2nd Propaideutic Surgical DepartmentLaikon University HospitalAthensGreece
  3. 3.4th Surgical Department, Attikon HospitalUniversity of AthensAthensGreece
  4. 4.1st Department of Propaedeutic Surgery, Hippokratio Hospital, School of MedicineUniversity of AthensAthensGreece
  5. 5.St Mark’s Hospital, & Academic InstituteHarrowLondon
  6. 6.Cell and Gene Therapy LaboratoryBiomedical Research Foundation of the Academy of Athens (BRF)AthensGreece

Personalised recommendations